NASDAQ:PCSA

Heatwurx Q4 2024 Earnings Results & Report

Heatwurx logo
$1.69 -0.01 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$1.42 -0.27 (-16.15%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Heatwurx beat analyst earnings expectations in its Q4 2024 results, released March 20, 2025. The company reported EPS of -$18.50 versus the -$23.00 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
After Market Closes
Conference Call
3:00 AM ET

Heatwurx EPS Results

Actual EPS
-$18.50
Consensus EPS
-$23.00
Beat/Miss
Beat by +$4.50
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Heatwurx Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Heatwurx Q4 2024 Earnings FAQ

Heatwurx (NASDAQ:PCSA) reported earnings of -$18.50 per share for Q4 2024, beating the consensus estimate of -$23.00. The report was announced on Thursday, March 20, 2025.

Heatwurx Earnings Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Heatwurx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Heatwurx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Heatwurx and other key companies, straight to your email.

About Heatwurx

Heatwurx (NASDAQ:PCSA) was an asphalt pavement repair technology company. It developed infrared-based equipment and repair methods intended to heat and reuse existing pavement, serving the road and pavement maintenance industry.

Heatwurx is a historical company name associated with the business now identified by Nasdaq ticker PCSA. The public company operates as Processa Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions.

View Heatwurx Profile